We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends Comment Period on Amending ANDA, 505(b)(2) Process
FDA Extends Comment Period on Amending ANDA, 505(b)(2) Process
In response to overwhelming requests from industry, the FDA is extending to June 8 the comment period on its draft rule overhauling the ANDA and 505(b)(2) approval processes.